Cancer is the leading cause of death in the Western world. The use of antibodies for cancer therapy has achieved considerable success. Recently, novel immunotherapies targeting the patient’s own immune system have shown strong clinical promise. Immunotherapy is believed to become the treatment backbone in up to 60% of cancers over the next 10 years. (source: World Cancer Report 2014; Immunotherapy, Citi Reseach, 2013)
ARGX-110 is a first-in-class SIMPLE Antibody™ with broad therapeutic potential across a range of cancers (blood and solid tumors) and severe autoimmune diseases. ARGX-110 has demonstrated a very promising safety profile and initial signs of biological activity in T-cell lymphoma (TCL), renal cell carcinoma, ovarian cancer and mesothelioma. Our current clinical development plan focuses on TCL and nasopharyngeal carcinoma (NPC), two indications with a very high unmet medical need.
ARGX-111 is a best-in-class SIMPLE Antibody™ with therapeutic potential for cancer metastases, targeting many cancer types such as gastric, renal, liver and brain.In Phase 1 clinical trials, ARGX-111 has demonstrated a very promising safety profile and initial signs of metabolic activity in patients with a specific genetic aberration (MET-amplification). Our current clinical development plan focuses on MET-amplified cancers.
ARGX-115 is a first-in-class SIMPLE Antibody™ with potential for cancer immunotherapy. ARGX-115 is currently in preclinical development and has been partnered with AbbVie, Inc. on April 20, 2016 under a Development and Exclusive License Option Agreement.